After AstraZeneca: 3 Other Opportunities For Pfizer

Now that the AstraZeneca deal is off the table, what three things can Pfizer investors look forward to?

May 27, 2014 at 2:30PM

Pfizer (NYSE:PFE) on Monday formally abandoned its attempts to acquire AstraZeneca (NYSE:AZN), the second-largest pharmaceutical company in the U.K. AstraZeneca rejected Pfizer's final £69.4 million ($117 milion) bid last week, dashing the company's hopes of lowering its corporate tax rate and expanding its oncology pipeline.


Source: Wikimedia Commons.

Looking beyond the AstraZeneca deal, Pfizer still has three major opportunities for growth that investors shouldn't overlook.

Three cancer drugs to watch
Pfizer's cancer pipeline might not be as impressive as AstraZeneca's, but the company has several treatments worth watching.

Sales of Xalkori, a treatment for a mutation of non-small cell lung cancer known as ALK, jumped 129% year over year to $282 million in 2013. Pfizer notably reported in March that the drug was more effective than chemotherapy in a phase 3 trial of previously untreated patients. Based on that new data, analysts at Cowen believe Xalkori could hit peak yearly sales of $1 billion by 2020.

Inlyta, a treatment for advanced kidney cancer that launched in the second half of 2012, generated $319 million in sales last year. Inlyta faces stiffer competition than Xalkori, but Barclays believes the drug could generate peak annual sales of $600 million by 2016.

Palbociclib, Pfizer's experimental treatment for ER+ (estrogen receptor positive), HER2- (human epidermal growth factor receptor 2 negative) breast cancer, is the third cancer drug to watch. Approximately 75% of all breast cancer cases fall into these two categories.

Palbociclib belongs to a new class of drugs known as CDK inhibitors, a category that also includes Novartis' LEE011 and Eli Lilly's LY2835219. Palbociclib is the most advanced of the three -- it is in phase 3 trials, and Pfizer plans to submit a new drug application to the FDA based on the drug's phase 2 data. Peak sales projections for palbociclib fall between $2 billion (Bernstein) and $6 billion (ISI).

One cholesterol drug to watch
Investors should also pay close attention to the three-way race in next-generation cholesterol treatments between Pfizer, Amgen (NASDAQ:AMGN), and Sanofi (NYSE:SNY)/Regeneron (NASDAQ:REGN). All of these companies are focused on bringing a new class of cholesterol drugs, known as PCSK9 inhibitors, to the market.

In the past, statins stopped the liver from producing LDL "bad" cholesterol, but could raise levels of PCSK9, an enzyme that degrades liver-based LDL receptors that regulate LDL levels. PCSK9 inhibitors attempt to lower levels of that enzyme so LDL receptors can do their job.

Pfizer's RN-316, Amgen's AMG 145, and Sanofi/Rengeneron's alirocumab are all in phase 3 trials. Expectations for the three drugs are high, with most peak sales estimates falling between $1 billion to $6 billion.

The importance of these three drugs can be seen in the sheer size of their trial groups. Pfizer and Sanofi/Regeneron's late-stage trials each consist of 22,000 patients, while Amgen's trials involve more than 4,000 patients. Although top-line data from these late-stage studies won't be known for some time, Pfizer reported in March that RN-316 in a phase 2b trial significantly reduced LDL cholesterol in statin-treated adults with high cholesterol.

One business division to watch
Pfizer's weakest business has always been its generics segment, which is now part of its newly formed global established pharmaceuticals, or GEP, operation. The GEP segment consists of generic drugs, biosimilars, patented drugs that will lose exclusivity in the near term, and partnerships with other generic-drug makers.

Last quarter, sales at the GEP segment fell 13% year over year to $6 billion, due primarily to generic competition for Detrol LA and Lipitor in the U.S. and Viagra in Europe. The termination of collaborations in Japan and Europe exacerbated the decline.

There has been speculation that Pfizer merged its generics business with additional businesses to make it more attractive to potential buyers. In January, Reuters reported that Valeant, Mylan, and Actavis were all interested in acquiring the GEP business, which accounted for 53% of Pfizer's first-quarter revenue.

Pfizer could use cash from selling the GEP business to invest in higher-growth areas, such as its aforementioned oncology and cholesterol treatments. It could also spin off the business and profit from an IPO, as it did with Zoetis.

The Foolish takeaway
Pfizer still has rich opportunities for top-line growth, even though its stock has remained flat over the past 12 months. New cancer treatments, a new cholesterol drug, and the possible sale of the GEP business could each generate billions of dollars.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers